Skip to content

The Morning Dispatch: Is the West Souring on China?

Plus, the latest numbers on the 2020 race.
The Dispatch Staff /
The Morning Dispatch: Is the West Souring on China?

Happy Friday! The last time an NFC North team traded up in the first round of the NFL draft to select a quarterback was a … mixed bag. You’ve got big shoes to fill, Jordan Love!

Quick Hits: Today’s Top Stories

  • As of Thursday night, there are now 869,170 confirmed cases of COVID-19 in the United States (a 3.1 percent increase from yesterday) and 49,887 deaths (a 6.6 percent increase from yesterday), according to the Johns Hopkins University COVID-19 Dashboard, leading to a mortality rate among confirmed cases of 5.7 percent (the true mortality rate is likely much lower due to incomplete testing regimens). Of 4,660,250 coronavirus tests conducted in the United States, 18.7 percent have come back positive. There are 123,621 Americans hospitalized with COVID-19 complications (a 1.5 percent increase from yesterday), and 80,203 have recovered from the virus (a 4.7 percent increase from yesterday).

  • A new report from the Centers for Disease Control estimates that 45.4 percent of American adults are at an increased risk of developing coronavirus-related complications due to cardiovascular disease, diabetes, respiratory disease, hypertension, or cancer.

  • We got some more harrowing unemployment figures Thursday, with an additional 4.4 million Americans filing claims in the last week. More than 26 million people have now filed jobless claims in recent weeks.

  • The House passed the latest $484 billion economic relief package—that also includes money for hospitals and coronavirus testing—by a vote of 388-5. President Trump is expected to sign the legislation into law as early as today.

  • Sens. Mitt Romney and Kyrsten Sinema sent a letter to CDC Director Robert Redfield expressing “deep concern” that the federal government is “behind the curve in assessing public health threat levels” due to the absence of “immediate visibility into population health data.” The U.S. “public health biosurveillance and data collection should be able to provide comprehensive, near real-time reporting,” they wrote, but it cannot currently do so.

  • Last week we linked to a STAT News story that indicated Gilead Science’s antiviral drug, remdesivir, was having some preliminary success in treating COVID-19 patients. The results of a Chinese clinical trial of the drug were less promising, according to a manuscript temporarily posted to the World Health Organization’s website. Gilead, however, maintained the data showed a “potential benefit.” Bottom line: Scientific research is messy, nonlinear, and requires much peer-review—be wary of drawing too many conclusions from single studies or trials.

U.K. Reconsiders Its Deal With Huawei

Remember Huawei? Back before this militant supervirus came and upended all our lives, we spent a good amount of time talking about the relationship between the Chinese telecom giant and the U.K.—and how Boris Johnson’s decision to let the company help build his country’s 5G data networks portended less secure data all over the world.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Newsletter selected

Click sign up to start receiving your newsletters.

More We Think You’d Like

Newsletter selected

Click sign up to start receiving your newsletters.

Loading